Treatment of Geographic Atrophy Secondary to AMD With Pegcetacoplan: Two-Year Outcomes From the Randomized Phase 3 OAKS and DERBY Trials (AAO 2022) - Apellis Medical Hub Canada

Treatment of Geographic Atrophy Secondary to AMD With Pegcetacoplan: Two-Year Outcomes From the Randomized Phase 3 OAKS and DERBY Trials

Share Via Email

Back to Conference Resources

GA Congress Presentations American Academy of Ophthalmology (AAO) 2022

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.